Development of carbohydrate based anticancer agents

Informations projet

CarboMed

N° de convention de subvention: 101082163

DOI

10.3030/101082163

Projet clôturé

Date de signature de la CE 22 Juillet 2022

Date de début 1 Septembre 2022

Date de fin 29 Février 2024

Financé au titre de

• European Research Council (ERC)

Coût total

Aucune donnée

Contribution de l’UE

€ 150 000,00

Coordonné par

STICHTING RADBOUD UNIVERSITEIT
Netherlands

Periodic Reporting for period 1 - CarboMed (Development of carbohydrate based anticancer agents)

Période du rapport: 2022-09-01 au 2024-02-29

Résumé du contexte et des objectifs généraux du projet

Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry, cancer immunology with the drug discovery and medicinal chemistry of our ERC project GlycoEdit, we found carbohydrate based inhibitors that selectively target the biosynthesis of the cancer-cell protecting carbohydrate coat. By doing so, it was found they it can severely cripple the cancer's ability to grow and metastasize and trigger immune mediated killing. Our lead candidate is a potent and selective metabolic inhibitor of the fucosylation biosynthesis pathway and therefore offers a rich and promising frontier for the development of a glycan-based therapy for cancer.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The CarboMed project has led to the assessment of the commercial viability of carbohydrate based inhibitors that could serve as next-generation therapeutics to treat cancer in the clinic.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

In this project, we have delivered technical and commercial proof-of-concept to ultimately enable clinical studies. The intellectual property is now licenced to GlycoTherapeutics B.V. which will further investigate the (pre)clinical potential of this technology.